In his latest piece on Alzheimer’s Disease (AD) drug Aducanumab’s winding journey to market, Dr Neil Cashman looks forward to the US FDA Advisory…

Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why…

Anette Margrethe Storstein MD PhD of the Norwegian Brain Council introduces the burden of neurodegenerative disease in Norway today, the ongoing…

In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment aducanumab’s torturous journey to market, Dr…

Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease…

Holmusk’s Nawal Roy outlines why a cure for Alzheimer’s Disease is the “Holy Grail” of medicine today, the reasons for so many biotech…

PharmaBoardroom recently spoke to CNS-focused Danish biopharma company Lundbeck’s EVP and Head of North America Peter Anastasiou, who highlighted…

Industry veteran Peter Anastasiou, executive VP and head of North America for Danish CNS specialist Lundbeck, outlines the performance of Lundbeck’s…

Biogen Mexico’s Luis Calderon discusses establishing the affiliate, the opportunities apparent in the Mexican neurodegenerative disease market, and…

UCB’s Omar Lugo Aguirre outlines the company’s response to the COVID-19 pandemic in Mexico, countering stigmas around neurodegenerative and mental…

Sara Montero, managing director of Lundbeck Mexico, Central America and Andean countries since January 2020, explains her key priorities and the…

Dr Li Shuai of pain- and CNS-focused Chinese biotech SIMR outlines the history of the company, the unmet medical needs it is seeking to address, its…